ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc (XERS)

7,41
0,01
(0,14%)
Geschlossen 26 Juni 10:00PM
7,5181
0,1081
(1,46%)
Nach Börsenschluss: 1:55AM

Xeris Biopharma Holdings Inc (XERS) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
7,5181
( 1,60% )
Gebot
5,73
Fragen
9,35
Volumen
1.918.660
7,34 Tagesbereich 7,615
4,52 52-Wochen-Bereich 10,08
Marktkapitalisierung
Handelsende
7,40
Handelsbeginn
7,41
Letzte Trade
12
@
7.41
Letzter Handelszeitpunkt
Finanzvolumen
US$ 14.310.190
VWAP
7,4584
Durchschnittliches Volumen (3 Mio.)
US$ 1.671.534
Ausgegebene Aktien
172.642.055
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
108,42
Gewinn pro Aktie (EPS)
0,06
Erlöse (LTM)
314,85M
Nettogewinn (LTM)
12,01M

Über Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric ... Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
Chicago, United States
Gegründet
2026
Xeris Biopharma Holdings Inc is listed in the Healthcare sector of the NASDAQ with ticker XERS. The last closing price for Xeris Biopharma was US$7,40. Over the last year, Xeris Biopharma shares have traded in a share price range of US$ 4,52 to US$ 10,08.

Xeris Biopharma currently has 172.642.055 shares in issue. The market capitalisation of Xeris Biopharma is US$1,30 billion. Xeris Biopharma has a price to earnings ratio (PE ratio) of 108.42.

XERS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.48816.943100995737.037.51816.8619530207.10284224CS
41.298120.86977491966.227.51815.8117757736.6336061CS
121.618127.42542372885.97.51815.75516107226.36230811CS
260.21812.987671232887.38.425.2518448096.54748729CS
522.858161.33261802584.6610.084.5221376656.94000368CS
1564.6181159.2448275862.910.081.4618801744.60720476CS
2603.148172.03890160184.3710.080.970118602093.70789141CS

XERS - Frequently Asked Questions (FAQ)

What is the current Xeris Biopharma Holdings Inc share price?
The current share price of Xeris Biopharma Holdings Inc is US$ 7,5181
How many Xeris Biopharma Holdings Inc shares are in issue?
Xeris Biopharma Holdings Inc has 172.642.055 shares in issue
What is the market cap of Xeris Biopharma Holdings Inc?
The market capitalisation of Xeris Biopharma Holdings Inc is USD 1,3B
What is the 1 year trading range for Xeris Biopharma Holdings Inc share price?
Xeris Biopharma Holdings Inc has traded in the range of US$ 4,52 to US$ 10,08 during the past year
What is the PE ratio of Xeris Biopharma Holdings Inc?
The price to earnings ratio of Xeris Biopharma Holdings Inc is 108,42
What is the cash to sales ratio of Xeris Biopharma Holdings Inc?
The cash to sales ratio of Xeris Biopharma Holdings Inc is 3,81
What is the registered address of Xeris Biopharma Holdings Inc?
The registered address for Xeris Biopharma Holdings Inc is 1375 West Fulton Street, Chicago, Illinois, 60607
What is the Xeris Biopharma Holdings Inc website address?
The website address for Xeris Biopharma Holdings Inc is www.xerispharma.com
Which industry sector does Xeris Biopharma Holdings Inc operate in?
Xeris Biopharma Holdings Inc operates in the Biotechnology & Life Sciences sector

XERS Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht